全文获取类型
收费全文 | 5602篇 |
免费 | 625篇 |
国内免费 | 170篇 |
专业分类
耳鼻咽喉 | 55篇 |
儿科学 | 220篇 |
妇产科学 | 142篇 |
基础医学 | 158篇 |
口腔科学 | 79篇 |
临床医学 | 1256篇 |
内科学 | 1260篇 |
皮肤病学 | 115篇 |
神经病学 | 355篇 |
特种医学 | 192篇 |
外科学 | 1613篇 |
综合类 | 23篇 |
一般理论 | 1篇 |
预防医学 | 328篇 |
眼科学 | 327篇 |
药学 | 45篇 |
肿瘤学 | 228篇 |
出版年
2023年 | 109篇 |
2021年 | 65篇 |
2020年 | 98篇 |
2019年 | 40篇 |
2018年 | 126篇 |
2017年 | 175篇 |
2016年 | 182篇 |
2015年 | 137篇 |
2014年 | 223篇 |
2013年 | 302篇 |
2012年 | 99篇 |
2011年 | 123篇 |
2010年 | 237篇 |
2009年 | 339篇 |
2008年 | 132篇 |
2007年 | 67篇 |
2006年 | 108篇 |
2005年 | 75篇 |
2003年 | 48篇 |
2002年 | 47篇 |
2001年 | 113篇 |
2000年 | 76篇 |
1999年 | 143篇 |
1998年 | 177篇 |
1997年 | 202篇 |
1996年 | 303篇 |
1995年 | 257篇 |
1994年 | 196篇 |
1993年 | 119篇 |
1992年 | 125篇 |
1991年 | 142篇 |
1990年 | 68篇 |
1989年 | 135篇 |
1988年 | 104篇 |
1987年 | 83篇 |
1986年 | 108篇 |
1985年 | 90篇 |
1984年 | 88篇 |
1983年 | 74篇 |
1982年 | 68篇 |
1981年 | 63篇 |
1980年 | 82篇 |
1979年 | 39篇 |
1978年 | 61篇 |
1977年 | 45篇 |
1976年 | 44篇 |
1975年 | 45篇 |
1972年 | 39篇 |
1964年 | 50篇 |
1963年 | 47篇 |
排序方式: 共有6397条查询结果,搜索用时 15 毫秒
101.
Wieslaw Bochenek MD John B. Rodgers Jr MD John A. Balint MB MRCP 《Digestive diseases and sciences》1971,16(10):865-872
The inhibitory effect of duodenal acidification and intraduodenal fat infusion on pentagastrin-stimulated gastric secretion in normal subjects and in patients with duodenal ulcer was studied. Intraduodenal infusion of acid resulted in inhibition of HCl secretion found to be significant only in ulcer patients. Pepsin output, although lower during the first 15 minutes of duodenal acidification, later increased. Intraduodenal infusion of olive oil resulted in significant inhibition of HCl and pepsin output in both groups of patients, which was maximal 45–60 minutes after the beginning of fat infusion. Gastric secretion was more readily inhibited in ulcer patients than in normal subjects; this difference was particularly evident in inhibition of pepsin secretion. In addition, decrease in concentration of HCl and pepsin was observed to be significant only in ulcer patients. Mechanisms by which duodenal acidification and fat inhibit gastric secretion are discussed. The results obtained suggest that secretin, which is probably responsible for inhibition after duodenal acidification, is not the inhibitor during inhibition by fat. The ulcer patients were found to have unimpaired mechanisms of inhibition by acid and fat. 相似文献
102.
John L. Reid DM Robert J. MacFadyen MD PhD Iain B. Squire MB Kennedy R. Lees MD 《The American journal of cardiology》1993,71(17):E57-E60
Angiotensin-converting enzyme (ACE) inhibitors improve survival in heart failure and delay progression to clinical heart failure in patients with left ventricular dysfunction after myocardial infarction. Increasing numbers of older patients are being considered for such treatment. However, there are reports of excessive and prolonged decreases in blood pressure (BP) after the first dose of some ACE inhibitors. We have studied the hemodynamics, pharmacokinetics, and neurohumoral responses to the first dose of oral captopril 6.25 mg, enalapril 2.5 mg, perindopril 2.0 mg, intravenous enalaprilat 1.5 mg, and perindoprilat 1.0 mg, compared with oral or intravenous placebo in 6 parallel groups of 12 elderly patients each with moderate-to-severe (New York Heart Association classes II-IV) heart failure. Oral dosing with active drugs led to different temporal responses. After captopril, there was an early short-lived decrease in BP. Enalapril led to a later long-lasting decrease, but perindopril was not different from placebo. Intravenous enalaprilat and intravenous perindoprilat each lowered BP to a similar extent. The doses of drugs used appeared to be comparable because plasma ACE inhibition was similar following perindopril or enalapril and also comparing perindoprilat and enalaprilat. These studies indicate that oral ACE inhibitors have different profiles of acute BP changes after the first dose. The explanation is not clear, but could include physicochemical differences in the interaction between prodrug ester and diacid metabolites leading to differences in tissue distribution and local enzyme inhibition. 相似文献
103.
Erectile Impotence in Chronic Alcoholics 总被引:1,自引:0,他引:1
Edward T. H. Tan BSc PhD Ralph H. Johnson DM DSc FRCP David G. Lambie BSc PhD Mithra E. Vijayasenan MB BS FRANZCP Edwin A. Whiteside MB ChB 《Alcoholism, clinical and experimental research》1984,8(3):297-301
Erectile impotence is a common complaint in alcoholics, but its mechanism is unknown. We have studied nocturnal penile erection in 13 alcoholics who complained of impotence. Seven had normal erections and their impotence was therefore psychogenic. Six were found to have diminished or absent nocturnal erections. Plasma concentrations of follicle-stimulating hormone (FSH) and luteinizing hormone (LH) were elevated in this latter group, with the exception of one patient who had only raised FSH. They also had more evidence of neurological damage than the other seven alcoholics, and two had evidence of damage to the parasympathetic nervous system. Investigation of erection during sleep in alcoholic patients with impotence may be useful in differentiating clinically between patients with psychogenic causes and patients with organic causes of impotence. 相似文献
104.
105.
106.
107.
David R. Matthews DPhil Carol Wysham MD Melanie Davies CBE April Slee PhD Maria Alba MD Mary Lee MPH Vlado Perkovic MBBS Kenneth W. Mahaffey MD Bruce Neal MB 《Diabetes, obesity & metabolism》2020,22(11):2199-2203
This study compared initiation of insulin and other antihyperglycaemic agents (AHAs) with canagliflozin versus placebo for participants with type 2 diabetes and a history/high risk of cardiovascular disease in the CANagliflozin cardioVascular Assessment Study (CANVAS) Program. After 1 year, fewer participants treated with canagliflozin versus placebo initiated any AHA (7% vs. 16%), insulin (3% vs. 9%) or any non-insulin AHA (5% vs. 12%) (P < .001 for all); overall AHA initiation rates increased over time but were consistently lower with canagliflozin compared with placebo. During the study, the likelihood of initiating insulin was 2.7 times lower for participants treated with canagliflozin compared with placebo (hazard ratio, 0.37; 95% CI: 0.31, 0.43; P < .001). The time difference between 10% of patients in the canagliflozin and placebo groups being initiated on insulin from the beginning of the trial was about 2 years. Time to initiation of other AHAs, including metformin, dipeptidyl peptidase-4 inhibitors, glucagon-like peptide-1 receptor agonists and sulphonylureas, was also delayed for canagliflozin versus placebo (P < .001 for each). Compared with placebo, canagliflozin delayed the need for initiation of other AHAs and delayed time to insulin therapy, an outcome that is important to many people with diabetes. 相似文献
108.
109.
110.